BioOrigin

BioOrigin is a biotechnology company focused on developing next-generation, "off-the-shelf" immune cell therapies using its proprietary induced pluripotent stem cell (iPSC) platform. The company specializes in creating chimeric antigen receptor natural killer (CAR-NK) cells designed to treat both hematological malignancies and solid tumors. By leveraging advanced gene editing and high-efficiency iPSC differentiation, BioOrigin aims to overcome the limitations of patient-derived (autologous) cell therapies, providing scalable and standardized treatments for global markets. Its lead programs focus on high-prevalence cancers where traditional CAR-T therapies have faced challenges, particularly in the solid tumor microenvironment.